Eikon Therapeutics filed for a U.S. initial public offering, positioning its platform and pipeline as an early test of whether recent market optimism can reopen the IPO window for biotech. The filing places the structure‑based drug discovery firm among the first companies to seek public capital after a cautious 2025 market. Eikon’s IPO will be watched as a bellwether for public investor demand in 2026; successful pricing could encourage additional offerings. The company’s filing details platform strengths and planned use of proceeds to expand discovery and translational efforts.